Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Work In Process (2016 - 2019)

Plus Therapeutics has reported Work In Process over the past 9 years, most recently at $662000.0 for Q1 2019.

  • Quarterly Work In Process rose 18.85% to $662000.0 in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $662000.0 through Mar 2019, up 18.85% year-over-year, with the annual reading at $555000.0 for FY2018, 23.13% down from the prior year.
  • Work In Process was $662000.0 for Q1 2019 at Plus Therapeutics, up from $555000.0 in the prior quarter.
  • Over five years, Work In Process peaked at $1.4 million in Q1 2015 and troughed at $418000.0 in Q3 2018.
  • The 5-year median for Work In Process is $839000.0 (2017), against an average of $876588.2.
  • Year-over-year, Work In Process surged 194.59% in 2015 and then crashed 53.21% in 2018.
  • A 5-year view of Work In Process shows it stood at $816000.0 in 2015, then rose by 25.12% to $1.0 million in 2016, then fell by 29.29% to $722000.0 in 2017, then dropped by 23.13% to $555000.0 in 2018, then rose by 19.28% to $662000.0 in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Work In Process are $662000.0 (Q1 2019), $555000.0 (Q4 2018), and $418000.0 (Q3 2018).